Phase 1 study of CB-839, a small molecule inhibitor of glutaminase in combination with paclitaxel in patients with triple negative breast cancer.
Phase 1 study of CB-839, a small molecule inhibitor of glutaminase, alone and in combination with everolimus in patients with renal cell cancer.
Presenter: Funda Meric-Benstam, MD,
About Calithera Biosciences
Jennifer McNealeyir@Calithera.com 650-870-1071